Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Changing burden of Acute Myeloid Leukemia in the United States: A 23-year national analysis

Qais Bin Abdul Ghaffar, Kendall Diebold, Omer Jamy

Blood (2025) 146 (Supplement 1): 6399.

https://doi.org/10.1182/blood-2025-6399

Published: 2025

Journal Articles

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

Joshua Knapp, Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza-Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Jorge Cortes, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 6398.

https://doi.org/10.1182/blood-2025-6398

Published: 2025

Journal Articles

Impact of sociodemographic factors on survival outcomes in chronic myeloid leukemia in the United States: A time-trend analysis

Qais Bin Abdul Ghaffar, Jorge Cortes, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 6396.

https://doi.org/10.1182/blood-2025-6396

Published: 2025

Journal Articles

Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia

Benjamin McCormick, Omer Jamy, Manuel Espinoza-Gutarra, Ravi Bhatia, Kimo Bachiashvili, Sravanti Rangaraju, Devan Parker, Sarah Worth, Pankit Vachhani, Razan Mohty

Blood (2025) 146 (Supplement 1): 1668.

https://doi.org/10.1182/blood-2025-1668

Published: 2025

Journal Articles

Outcomes of adult T-cell acute lymphoblastic leukemia/lymphoma in a real-world cohort: A single institution experience in the deep south

Maris Hardee, Jay Jarodiya, Kimo Bachiashvili, Ravi Bhatia, Manuel Espinoza-Gutarra, Omer Jamy, Razan Mohty, Pankit Vachhani, Sravanti Rangaraju

Blood (2025) 146 (Supplement 1): 8084.

https://doi.org/10.1182/blood-2025-8084

Published: 2025

Journal Articles

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

Blood (2025) 146 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2025-2396

Published: 2025

Journal Articles

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Blood (2025) 146 (Supplement 1): 874.

https://doi.org/10.1182/blood-2025-874

Published: 2025

Journal Articles

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2025-3365

Published: 2025

Journal Articles

Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax

Razan Mohty, Kendall Diebold, Todd Mudd, Maris Hardee, Jay Jarodiya, Katherine Parks, Kimo Bachiashvili, Manuel Espinoza-Gutarra, Sravanti Rangaraju, Pankit Vachhani, Omer Jamy

Blood (2025) 146 (Supplement 1): 5272.

https://doi.org/10.1182/blood-2025-5272

Published: 2025

Journal Articles

Phase 2 study of SLS009 in combination with azacitidine and venetoclax for relapsed/refractory AML with MDS-related changes (AML-MR) after prior venetoclax treatment

Joshua Zeidner, Omer Jamy, Bradley Christensen, Sharif Khan, Dragan Cicic, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2025-3423

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Blood (2025) 146 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2025-3775

Published: 2025

Journal Articles

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Aaron Logan, Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly

Blood (2025) 146 (Supplement 1): 516.

https://doi.org/10.1182/blood-2025-516

Published: 2025

Journal Articles

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Elias Jabbour, Timothy Hughes, Richard Van Etten, David Andorsky, Gonzalo Carreño, Philipp le Coutre, Omer Jamy, Pilar Giraldo, Dong-Wook Kim, Vivian Oehler, Andreas Hochhaus, Jorge Cortes, Michael Mauro, Tonya Marmon, Leanne Holes, Emil Kuriakose, Hagop Kantarjian, Delphine Rea

Blood (2025) 146 (Supplement 1): 901.

https://doi.org/10.1182/blood-2025-901

Published: 2025

Journal Articles

Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia

Todd Mudd, Kendall Diebold, Sravanti Rangaraju, Kimo Bachiashvili, Pankit Vachhani, Manuel Espinoza-Gutarra, Razan Mohty, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 5220.

https://doi.org/10.1182/blood-2025-5220

Published: 2025

Journal Articles

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Blood (2025) 146 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2025-2715

Published: 2025

Journal Articles

Improved outcomes with low-dose hypomethylating agent plus venetoclax as post-transplant maintenance in patients undergoing reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for myeloid malignancies

Kendall Diebold, Todd Mudd, Maris Hardee, Haley Thigpen, Manuel Espinoza-Gutarra, Antonio Di Stasi, Donna Salzman, Razan Mohty, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 4261.

https://doi.org/10.1182/blood-2025-4261

Published: 2025

Journal Articles

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Blood (2024) 144 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2024-210263

Published: 2024

Journal Articles

Superior Survival with Intensive Chemotherapy, Compared to Hypomethylating Agent + Venetoclax, in Patients with Intermediate/Adverse Risk Acute Myeloid Leukemia Unable to Proceed to Transplant

Kendall Diebold, Todd Mudd, Jay Jarodiya, Katherine Parks, Maris Hardee, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Manuel Espinoza-Gutarra, Razan Mohty, Ravi Bhatia, Omer Jamy

Blood (2024) 144 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2024-204120

Published: 2024

Journal Articles

Outcomes and Clinical Characteristics of Adult Patients with Transplant Associated Thrombotic Microangiopathy: A Single Center Experience

Manuel Espinoza-Gutarra, Omer Jamy, Razan Mohty, Lauren Kelly Shea, Donna Salzman, Antonio Di Stasi, Ravi Bhatia, Zaid Al-Kadhimi, Sumithira Vasu

Blood (2024) 144 (Supplement 1): 7290.

https://doi.org/10.1182/blood-2024-206687

Published: 2024

Journal Articles

Impact of Sociodemographic Factors on Mortality in Acute Myeloid Leukemia in the United States: A Time-Trend Analysis

Muhammad Faisal Aslam, Muhammad Hisham Khan Wazir, Asfand Yar Cheema, Omer Jamy

Blood (2024) 144 (Supplement 1): 5186.

https://doi.org/10.1182/blood-2024-212278

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Changing burden of Acute Myeloid Leukemia in the United States: A 23-year national analysis

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

Impact of sociodemographic factors on survival outcomes in chronic myeloid leukemia in the United States: A time-trend analysis

Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia

Outcomes of adult T-cell acute lymphoblastic leukemia/lymphoma in a real-world cohort: A single institution experience in the deep south

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax

Phase 2 study of SLS009 in combination with azacitidine and venetoclax for relapsed/refractory AML with MDS-related changes (AML-MR) after prior venetoclax treatment

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Improved outcomes with low-dose hypomethylating agent plus venetoclax as post-transplant maintenance in patients undergoing reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for myeloid malignancies

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Superior Survival with Intensive Chemotherapy, Compared to Hypomethylating Agent + Venetoclax, in Patients with Intermediate/Adverse Risk Acute Myeloid Leukemia Unable to Proceed to Transplant

Outcomes and Clinical Characteristics of Adult Patients with Transplant Associated Thrombotic Microangiopathy: A Single Center Experience

Impact of Sociodemographic Factors on Mortality in Acute Myeloid Leukemia in the United States: A Time-Trend Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only